Calendrier des promotions Spyre Therapeutics, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc., биотехнологическая компания, специализируется на продвижении линейки терапевтических средств на основе антител для лечения воспалительных заболеваний кишечника путем объединения инженерии антител, рациональных терапевтических комбинаций и прецизионных медицинских подходов к отбору пациентов. В портфолио компании входят антитела с увеличенным периодом полураспада, нацеленные на a4β7, TL1A и IL-23. Компания ранее была известна как Aeglea BioTherapeutics, Inc. и сменила название на Spyre Therapeutics, Inc. в ноябре 2023 года. Spyre Therapeutics, Inc. plus de détails| IPO date | 2016-04-07 |
|---|---|
| ISIN | US00773J2024 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.spyre.com |
| Цена ао | 35.99 |
| Changement de prix par jour: | -1.66% (24.07) |
|---|---|
| Changement de prix par semaine: | -0.7963% (23.86) |
| Changement de prix par mois: | -14.7% (27.75) |
| Changement de prix sur 3 mois: | -16.92% (28.49) |
| Changement de prix sur six mois: | -0.5044% (23.79) |
| Changement de prix par an: | +9.99% (21.52) |
| Evolution du prix sur 3 ans: | +536.29% (3.72) |
| Evolution du prix sur 5 ans: | +202.3% (7.83) |
| Evolution des prix sur 10 ans: | -0% (23.67) |
| Evolution des prix depuis le début de l'année: | -30.71% (34.16) |
|
|
Sous-estimation
|
Efficacité
|
|||||||||||||||||||||||||||||||||||||
Dividendes
|
Devoir
|
Impulsion de croissance
|
|||||||||||||||||||||||||||||||||||||
| Établissements | Volume | Partager, % |
|---|---|---|
| Driehaus Capital Management, LLC | 800853 | 19.78 |
| Franklin Resources, Inc. | 687090 | 16.97 |
| Fairmount Funds Management LLC | 378421 | 9.35 |
| Polar Capital Holdings PLC | 300000 | 7.41 |
| Wellington Management Group, LLP | 299929 | 7.41 |
| VR Adviser, LLC | 295034 | 7.29 |
| Affinity Asset Advisors, LLC | 242297 | 5.98 |
| Logos Global Management LP | 210000 | 5.19 |
| EcoR1 Capital, LLC | 199996 | 4.94 |
| Suvretta Capital Management, LLC | 162395 | 4.01 |
| ETF | Partager, % | Rentabilité pour l'année, % | Dividendes, % |
|---|---|---|---|
| iShares Morningstar Small-Cap Value ETF | 0.02406 | 201.65 | 2.50476 |
| iShares Morningstar Small Cap Value ETF | 0.02406 | 26.7 | 2.50476 |
| iShares Morningstar Small-Cap ETF | 0.02198 | 391.25 | 1.60498 |
| iShares Morningstar Small-Cap ETF | 0.02198 | 30.1 | 1.60498 |
| iShares Morningstar Small-Cap Growth ETF | 0.02 | 33.63 | 0.72598 |
| iShares Morningstar Small-Cap Growth ETF | 0.02 | 587.89 | 0.72598 |
iShares Russell 2000 Growth ETF
|
0.00646 | 38.04 | 0.6026 |
| iShares Russell 3000 ETF | 0.00187 | 24.83 | 1.43482 |
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
|---|---|---|---|
| Dr. Cameron Turtle DPHIL, Ph.D. | CEO & Director | 674.17k | 1990 (35 années) |
| Mr. Scott L. Burrows | Chief Financial Officer | 331.81k | 1977 (48 années) |
| Dr. Janet Gunzner-Toste M.B.A., Ph.D. | Senior Vice President of Operations | N/A | |
| Mr. Eric McIntyre | Vice President of Finance & Investor Relations | N/A | |
| Ms. Heidy Abreu King-Jones J.D., L.L.M. | Chief Legal Officer & Corporate Secretary | 568.87k | 1983 (42 année) |
| Mr. James Myers | Vice President of Quality & Compliance | N/A | |
| Dr. Kelly Boothe Ph.D. | Senior Director of Corporate Communications & Investor Relations | N/A | |
| Dr. Justin LaFountaine Ph.D. | Senior Vice President of Corporate Development | N/A | |
| Mr. Brian Connolly | Chief Technical Officer | N/A | |
| Ms. Melissa Cooper | Senior Vice President of People | N/A |
Adresse: United States, Waltham. MA, 221 Crescent Street - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.spyre.com
Site web: https://www.spyre.com
